CClinicalTrials.gg
Not yet recruitingNCT07575880Mai Poumons 26Updated May 13, 2026

Screening for Obstructive Respiratory Disorders in the General Population During the "Mai Poumon 2026" Prevention Campaign: Prevalence and Impact on the Care Pathway

An observational study in Chronic Obstructive Lung Disease and Airflow Obstruction, sponsored by Centre Hospitalier de la côte Basque. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Centre Hospitalier de la côte Basque · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population.

Read the detailed description

Chronic Obstructive Pulmonary Disease (COPD), a chronic bronchial disease characterized by irreversible airway obstruction, represents a major public health issue. It is currently the fifth leading cause of death worldwide and, according to the World Health Organization (WHO), is expected to become the third leading cause by 2030. Diagnosis is currently based on spirometry, which reveals an obstructive ventilatory disorder (OVD) defined by a forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) ratio of less than 0.7. However, limited access to this examination can make the diagnosis of COPD difficult. Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. A French study involving 424 patients hospitalized for a COPD exacerbation found that 21.9% had not been diagnosed previously, meaning they entered the disease during a severe exacerbation. The main challenge, therefore, lies in the early identification of COPD patients, particularly through the use of validated self-questionnaires (e.g., Haute Autorité de Santé). We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population. The secondary objectives are: to compare the clinical characteristics of patients with and without AO / with and without PRISm (depending on sample size). To identify risk factors for AO and/or PRISm (depending on sample size) (female sex, advanced age, BMI, active smoking, respiratory symptoms). To estimate the prevalence of "undiagnosed" subjects, defined as the presence of OVD without any known respiratory history, and to study their clinical characteristics. We plan to follow up with participants at 6 months through a telephone contact to assess the practical impact of this screening day and to determine the proportion of those who have received a consultation with a general practitioner, a pulmonologist, or the introduction of a treatment.

02

Conditions studied

  • Chronic Obstructive Lung Disease
  • Airflow Obstruction
03

In context

Pulmonary Disease, Chronic Obstructive

4,131 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 697 are open to participants now.

This study's planned enrollment of 200 is above the median of 180 across 1,066 observational studies indexed under Pulmonary Disease, Chronic Obstructive.

Browse Pulmonary Disease, Chronic Obstructive studies →

Lead sponsor

Centre Hospitalier de la côte Basque is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Population attending the "9 Mai Poumon 2026" prevention campaign

Inclusion criteria

  • Age ≥ 18 years
  • Participating to the prevention campain "Mai Poumons 2026" on 09 Mai 2026

Exclusion criteria

  • Contre-indication to perform a spirometry : hemoptysy, pneumothorax, myocardal infarction \<1month, thoracic anevrism, recent ophtalmologic, abdominal or thoracic surgery
  • Unable to perform a spirometry (understanding, coordination)
  • Patient under legal protection
  • Patient pregnant or breasting
  • Not affiliating to public healthcare
  • Patient deprived of liberty
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testSpirometry

    Spirometry to identify airflow obstruction and PRISm (Preserved ration impaired spirometry)

06

What researchers measure

Primary outcomes

  1. Prevalence of newly diagnosed airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population

    Percentage of AO and PRISm detected

    Time frame: On the day of inclusion

Secondary outcomes

  1. Description of the clinical characteristics of patients with and without Airflow Obstruction / with and without PRISm

    Percentage of presence of symptoms, specific treatment

    Time frame: At the day of inclusion

  2. Description of the population participating to the prevention campaing

    Percentage of presence of tabagism

    Time frame: At the day of inclusion

  3. Evaluation of the number of patients diagnosed with airflow obstruction or Prism and who attend a consult with a medical doctor after the prevention campain

    Percentage of patients with a medical follow-up at 6 months

    Time frame: At Month 6

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07575880
Lead sponsor
Centre Hospitalier de la côte Basque
Responsible party
Dr SABATINI Marielle (Pneumologist, Centre Hospitalier de la côte Basque) — Principal investigator
First posted
May 8, 2026
Start date
May 9, 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 13, 2026

Study contacts

Séverine LABARRERE
Contact
slabarrere@ch-cotebasque.fr
+33559443828

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion